5. Progressive supranuclear palsy Clinical trials / Disease details
Clinical trials : 95 / Drugs : 119 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04539041 (ClinicalTrials.gov) | February 16, 2021 | 25/8/2020 | Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy | A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy (PSP) | Drug: antisense oligonucleotide;Drug: placebo | Novartis Pharmaceuticals | NULL | Recruiting | 40 Years | 75 Years | All | 66 | Phase 1 | United States;Canada;Germany;United Kingdom |